Tags

Type your tag names separated by a space and hit enter

An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.
J Infect Public Health. 2020 Oct; 13(10):1405-1414.JI

Abstract

Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease -19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event. No specific antivirals are currently available for COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The treatments for COVID-19 are mainly based on the experiences of similar virus such SARS-CoV, MERS-CoV, HIV and influenza viruses. Scientists have taken great efforts to investigate the effective methods for the treatment of COVID-19. Up to now, there are over 1000 clinical studies for COVID-19 all over the world. In this article, we reviewed the current options for COVID-19 therapy including small molecules such as Remdesivir, Favipiravir, Lopinavir/Ritonavir etc, peptide inhibitors of ACE2, Traditional Chinese Medicines and Biologics such as SARS-CoV-2-specific neutralizing antibodies, mesenchymal stem cells and vaccines etc. Meanwhile, we systematically reviewed their clinical safety, clinical applications and progress of antiviral researches. The therapeutic effect of these antiviral drugs is summarized and compared, hoping to provide some ideas for clinical options of COVID-19 treatment and also provide experiences for the life-threatening virus diseases in the future.

Authors+Show Affiliations

Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, PR China.State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, PR China; Pingshan Translational Medicine Center, Shenzhen Bay Laboratory, Shenzhen, PR China. Electronic address: lizg@pkusz.edu.cn.Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, PR China. Electronic address: kafkaliu@163.com.

Pub Type(s)

Journal Article
Systematic Review

Language

eng

PubMed ID

32684351

Citation

Wang, Dongyuan, et al. "An Overview of the Safety, Clinical Application and Antiviral Research of the COVID-19 Therapeutics." Journal of Infection and Public Health, vol. 13, no. 10, 2020, pp. 1405-1414.
Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health. 2020;13(10):1405-1414.
Wang, D., Li, Z., & Liu, Y. (2020). An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. Journal of Infection and Public Health, 13(10), 1405-1414. https://doi.org/10.1016/j.jiph.2020.07.004
Wang D, Li Z, Liu Y. An Overview of the Safety, Clinical Application and Antiviral Research of the COVID-19 Therapeutics. J Infect Public Health. 2020;13(10):1405-1414. PubMed PMID: 32684351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. AU - Wang,Dongyuan, AU - Li,Zigang, AU - Liu,Yihui, Y1 - 2020/07/13/ PY - 2020/04/03/received PY - 2020/06/27/revised PY - 2020/07/07/accepted PY - 2020/7/21/pubmed PY - 2020/10/21/medline PY - 2020/7/21/entrez KW - Antiviral research KW - COVID-19 KW - Clinical efficacy KW - SARS-CoV-2 KW - Safety SP - 1405 EP - 1414 JF - Journal of infection and public health JO - J Infect Public Health VL - 13 IS - 10 N2 - Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease -19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event. No specific antivirals are currently available for COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The treatments for COVID-19 are mainly based on the experiences of similar virus such SARS-CoV, MERS-CoV, HIV and influenza viruses. Scientists have taken great efforts to investigate the effective methods for the treatment of COVID-19. Up to now, there are over 1000 clinical studies for COVID-19 all over the world. In this article, we reviewed the current options for COVID-19 therapy including small molecules such as Remdesivir, Favipiravir, Lopinavir/Ritonavir etc, peptide inhibitors of ACE2, Traditional Chinese Medicines and Biologics such as SARS-CoV-2-specific neutralizing antibodies, mesenchymal stem cells and vaccines etc. Meanwhile, we systematically reviewed their clinical safety, clinical applications and progress of antiviral researches. The therapeutic effect of these antiviral drugs is summarized and compared, hoping to provide some ideas for clinical options of COVID-19 treatment and also provide experiences for the life-threatening virus diseases in the future. SN - 1876-035X UR - https://www.unboundmedicine.com/medline/citation/32684351/An_overview_of_the_safety_clinical_application_and_antiviral_research_of_the_COVID_19_therapeutics_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1876-0341(20)30570-0 DB - PRIME DP - Unbound Medicine ER -